AbbVie Q2 2026 Earnings
Adj EPS $3.65 (est $3.61) - Net Rev. $16.99B (est $16.77B) - Skyrizi Rev $5.51B (est $5.43B) - RINVOQ Rev. $2.53B (est $2.48B) - Humira Rev $756M (est $734.1M) - Imbruvica $532M (est $563.2M) - Sees FY Adj EPS $13.87 To $14.07, Saw $13.91 To $14.11 - Yr View Incl Unfavourable Impact Of $0.58/SHR ON IPR&D - Yr View Incl $0.14/SHR Dilutive Impact On Apogee Deal
Story updates
12:03:15 PM UTC
SquawkNews
Adj EPS $3.65 (est $3.61) - Net Rev. $16.99B (est $16.77B) - Skyrizi Rev $5.51B (est $5.43B) - RINVOQ Rev. $2.53B (est $2.48B) - Humira Rev $756M (est $734.1M) - Imbruvica $532M (est $563.2M) - Sees FY Adj EPS $13.87 To $14.07, Saw $13.91 To $14.11 - Yr View Incl Unfavourable Impact Of $0.58/SHR ON IPR&D - Yr View Incl $0.14/SHR Dilutive Impact On Apogee Deal
Adj EPS $3.65 (est $3.61) - Net Rev. $16.99B (est $16.77B) - Skyrizi Rev $5.51B (est $5.43B) - RINVOQ Rev. $2.53B (est $2.48B) - Humira Rev $756M (est $734.1M) - Imbruvica $532M (est $563.2M) - Sees FY Adj EPS $13.87 To $14.07, Saw $13.91 To $14.11 - Yr View Incl Unfavourable Impact Of $0.58/SHR ON IPR&D - Yr View Incl $0.14/SHR Dilutive Impact On Apogee Deal